We narrowed to 2,692 results for: ICL

#137135-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-oScarlet (#137135). In addition to the viral particles, you will also receive purified pAAV-Ef1a-oScarlet plasmid DNA. EF1a-driven expression of oScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#185388-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-GRAB_OTmut (#185388). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OTmut plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) control sensor GRAB_OTmut in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

Oct. 21, 2024

Academic Institutions and Nonprofits only

#55638-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-vCre (#55638). In addition to the viral particles, you will also receive purified pAAV-EF1a-vCre plasmid DNA. EF1a-driven expression of VCre. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Nov. 12, 2020

Academic Institutions and Nonprofits only

#185388-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_OTmut (#185388). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OTmut plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) control sensor GRAB_OTmut in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

June 26, 2024

Academic Institutions and Nonprofits only

#218873-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-GFAP-iGABASnFR2(no bind)-WPRE (#218873). In addition to the viral particles, you will also receive purified pGP-AAV-GFAP-iGABASnFR2(no bind)-WPRE plasmid DNA. GFAP-driven expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#130995-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-ChRmine-mScarlet-Kv2.1-WPRE (#130995). In addition to the viral particles, you will also receive purified pAAV-hSyn-ChRmine-mScarlet-Kv2.1-WPRE plasmid DNA. hSyn-driven, soma-targeted ChRmine-mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Jan. 6, 2022

Academic Institutions and Nonprofits only

#105677-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Aug. 17, 2018

Academic Institutions and Nonprofits only

#130991-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-mScarlet-Kv2.1-WPRE (#130991). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-mScarlet-Kv2.1-WPRE plasmid DNA. CamKIIa-driven, soma-targeted ChRmine-mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Jan. 6, 2022

Academic Institutions and Nonprofits only

#45580-AAV5

Ready-to-use AAV5 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

Nirao Shah, Jim Wells

Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

Sept. 25, 2020

Academic Institutions and Nonprofits only

#130998-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE (#130998). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of ChRmine-mScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2024

Academic Institutions and Nonprofits only

#108912-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-ChroME-ST-P2A-H2B-mRuby3 (#108912). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-ChroME-ST-P2A-H2B-mRuby3 plasmid DNA. CAG-driven, Cre-dependent ChroME-ST-P2A-H2B-mRuby3 expression. These AAV preparations are suitable purity for injection into animals.

Hillel Adesnik

Mardinly et al Nat Neurosci. 2018 Apr 30. pii: 10.1038/

Nov. 20, 2018

Academic Institutions and Nonprofits only

#55641-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Dec. 18, 2024

Academic Institutions and Nonprofits only

#71760-AAV1

Ready-to-use AAV1 particles produced from pAAV hSyn FLEx mGFP-2A-Synaptophysin-mRuby (#71760). In addition to the viral particles, you will also receive purified pAAV hSyn FLEx mGFP-2A-Synaptophysin-mRuby plasmid DNA. Syn-driven, Cre-dependent expression of membrane-bound GFP and the presynaptic protein synaptophysin fused to mRuby. These AAV preparations are suitable purity for injection into animals.

Liqun Luo

Beier et al Cell. 2015 Jul 30;162(3):622-34. doi: 10

May 5, 2021

Academic Institutions and Nonprofits only

#105677-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Oct. 21, 2024

Academic Institutions and Nonprofits only

#174007-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST (#174007). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST plasmid DNA. Syn-driven, Cre-dependent expression of calcium sensor GCaMP8s and soma-targeted ChrimsonR. These AAV preparations are suitable purity for injection into animals.

Mark Histed

LaFosse et al eNeuro. 2023 Mar 29;10(3):ENEURO.0378-22

May 4, 2023

Academic Institutions and Nonprofits only

#119741-AAV9

Ready-to-use AAV9 particles produced from AAV SYN flex PSAM4 GlyR IRES EGFP (#119741). In addition to the viral particles, you will also receive purified AAV SYN flex PSAM4 GlyR IRES EGFP plasmid DNA. Synapsin-driven, Cre-dependent expression of PSAM4 GlyR IRES EGFP for neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Magnus et al Science. 2019 Mar 14. pii: science.aav52

Jan. 26, 2021

Academic Institutions and Nonprofits only

#171027-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO-ChrimsonR-tdTomato (#171027). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-ChrimsonR-tdTomato plasmid DNA. Flp-dependent, Ef1a-driven expression of ChrimsonR-tdTomato fusion for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

June 26, 2024

Academic Institutions and Nonprofits only

#104061-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-CAG-NLS-GFP (#104061). In addition to the viral particles, you will also receive purified pAAV-CAG-NLS-GFP plasmid DNA. CAG-driven NLS-GFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

March 5, 2019

Academic Institutions and Nonprofits only

#106174-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynapsin.SF-iGluSnFR.A184S (#106174). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.A184S plasmid DNA. hSynapsin driven SF-iGluSnFR.A184S glutamate sensor. The A184S mutant has a higher glutamate affinity. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 14, 2024

Academic Institutions and Nonprofits only

#105669-AAV1

Ready-to-use AAV1 particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

July 17, 2018

Academic Institutions and Nonprofits only